Loading...
NPI 1194971085 · Union, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Lincoln Diagnostics LLC is a clinical medical laboratory provider located in Union, New Jersey. This profile covers 222 Medicare and 320 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Lincoln Diagnostics LLC |
| Address | 1023 Commerce Ave |
| City | Union |
| State | NJ |
| ZIP | 07083 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 12, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $24.3M |
| Medicare | $3.2M |
LINCOLN DIAGNOSTICS LLC operates as a clinical medical laboratory with a strong emphasis on molecular infectious-disease testing alongside routine clinical chemistry and pathology; its top Medicare and Medicaid codes are dominated by amplified nucleic acid/probe techniques (for example U0003/U0004/U0005, 87635/87636/87631, and 87798) while also billing common panels and assays such as 82306, 83036, 80061 and 88305. This mix indicates a dual capability: high-throughput public-health style pathogen testing and ongoing outpatient diagnostic services.
Revenue concentration on Medicare is meaningfully focused: the top three Medicare codes (87798, 88120, U0004) account for 40.3% of the provider's total Medicare revenue, with listed Medicare revenues of $483.2K (87798), $284.5K (88120), and $236.7K (U0004). That concentration shows a reliance on a relatively small set of tests for a large share of Medicare receipts.
On the Medicaid side the provider is even more concentrated: the top three Medicaid codes (U0003, 87798, 87631) account for 59.7% of Medicaid revenue, with reported Medicaid revenues of $5.6M (U0003), $4.7M (87798), and $1.8M (87631). This indicates Medicaid business is heavily driven by SARS‑CoV‑2 and multiplex respiratory testing.
The payer mix is heavily weighted toward Medicaid: total Medicaid revenue is $24.3M compared with total Medicare revenue of $3.2M, making Medicaid by far the larger revenue source for this provider. In practice this means the lab’s operational and contract priorities are likely influenced more by state Medicaid volume and reimbursement than by Medicare.
Competitive standing is mixed by payer and code: for Medicare, some molecular codes show exceptional relative volume — for example 87635 is described as a 100th percentile, “extreme outlier, far above typical national volume” (rank #45 of 9976), and 87636 ranks in the 99th percentile nationally (rank #23 of 2192). These signals suggest the lab is a nationally notable outlier on selected SARS‑CoV‑2 PCR testing lines even if its overall Medicare revenue ($3.2M) is modest.
Within New Jersey Medicaid the provider ranks as a major in COVID and respiratory testing: U0003 ranks #14 of 127 in‑state (90th percentile) and 87798 ranks #6 of 88 (94th percentile), while 87486 and 87581 are state-level outliers (each rank #2 of 64; 98th percentile). These rankings, together with the large Medicaid dollar volumes reported for U0003 ($5.6M) and 87798 ($4.7M), indicate substantial market share in state SARS‑CoV‑2 and related respiratory testing.
Service breadth includes both high-throughput pandemic-era assays and standard outpatient diagnostics: Medicaid claims include very large counts for U0003 (85.8K claims) and U0005 (82.4K claims) as well as high claim volumes for routine analytes like 82306 (32.7K claims) and 82607 (29.1K claims). The coexistence of PLA code 0202U and widespread panel/CMP/CBC codes suggests the lab supports specialized multiplex platforms alongside high-volume clinical chemistry workflows.
The provider has an established operational history, with NPI enumeration dated 2008-08-12 (~18 years ago), which aligns with sustained contracting and the ability to scale volumes for Medicaid (total $24.3M) and targeted national prominence on specific Medicare molecular tests. Tenure combined with the observed payer and code mix supports the interpretation of a mature laboratory with deep state Medicaid integration and selective national prominence on pandemic-related PCR testing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
222 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 14,210 | $30 | $483.2K |
| 88120 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for manual morphometric analysis, looking at the number and… | 540 | $520 | $284.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3,200 | $70 | $236.7K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 1,370 | $140 | $192.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 2,980 | $50 | $148.9K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,010 | $140 | $140.8K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 1,700 | $60 | $109K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 2,650 | $40 | $100.8K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 2,860 | $30 | $83.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 3,140 | $30 | $78.6K |
Showing 1–10 of 222
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 222 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
222 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 7 | 40 | 1,760 | $30 | $284.3K |
| 88120 | 5 | 20 | 200 | $350 | $278K |
| 87150 | 10 | 10 | 430 | $30 | $175.3K |
| 86769 | 6 | 20 | 100 | $40 | $140.5K |
| G0483 | 26 | 40 | 60 | $240 | $134.7K |
| U0004 | 4 | 20 | 360 | $70 | $116.2K |
| 86480 | 10 | 20 | 50 | $60 | $110.8K |
| U0003 | 47 | 80 | 110 | $70 | $101.7K |
| 86235 | 8 | 40 | 160 | $20 | $95.2K |
| G0480 | 38 | 50 | 260 | $110 | $91.8K |
Showing 1–10 of 222
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
320 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 85,820 | $70 | $5.6M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 53,230 | $90 | $4.7M |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 34,080 | $50 | $1.8M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 82,380 | $20 | $1.6M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 16,020 | $50 | $816.9K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 46,240 | $10 | $647.3K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 32,670 | $20 | $555.4K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 46,230 | $10 | $554.7K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 27,540 | $20 | $523.2K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 5,030 | $70 | $372.5K |
Showing 1–10 of 320
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
320 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 14 | 130 | 3,180 | $60 | $4.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 23 | 30 | 2,020 | $110 | $2M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 7 | 40 | 590 | $20 | $1.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 35 | 150 | 3,680 | $30 | $1.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 35 | 40 | 1,690 | $70 | $1.4M |
| 86480 | The lab analyst performs a test to evaluate a cell mediated immunity gamma interferon antigen response to certain tuberculosis, or TB, antibodies. | 8 | 40 | 810 | $30 | $1.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 19 | 70 | 4,800 | $50 | $1M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 15 | 120 | 900 | $20 | $971.9K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 15 | 120 | 940 | $20 | $957.4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 65 | 110 | 1,810 | $50 | $930.1K |
Showing 1–10 of 320
Other providers in the same ZIP code as Lincoln Diagnostics LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.